Clinical trial · people
Retatrutide lowered ANGPTL3/8 in step with triglycerides and LDL-C
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This paper points to the glucagon receptor side of retatrutide as one possible reason its blood fat and LDL cholesterol drops happen, through lower ANGPTL3/8.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2025
- Journal
- Diabetes Obes Metab
What they tested
The team tested whether retatrutide lowers blood triglycerides and LDL-C partly by reducing a blood protein complex called ANGPTL3/8.
How the study was done
A post hoc analysis, meaning a look back at data after the trials ended, of two phase 2 retatrutide trials: one in people with type 2 diabetes and one in people with obesity or overweight without diabetes. The team also ran lab tests on primary human hepatocytes, liver cells taken from people, exposed to retatrutide, GIP, GLP-1, glucagon and an antibody that blocks the glucagon receptor.

Model. Individual results vary.
What they found
In people with type 2 diabetes, ANGPTL3/8 fell with the 8 and 12 mg retatrutide doses. In people with obesity or overweight without diabetes, it fell with the 1, 4, 8 and 12 mg doses. In both groups, the drop in ANGPTL3/8 tracked the drops in triglycerides (blood fats) and LDL-C (LDL cholesterol) seen with retatrutide. In lab-grown human liver cells, both glucagon and retatrutide cut ANGPTL3/8 release, and the glucagon receptor-blocking antibody stopped that effect.
What it doesn’t show
This was a post hoc look at two trials, and changes that move together do not show that one causes the other. The liver cell results come from lab work, not from people.
The paper
Wen et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.